Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones

References

• HaasWPillarCMTorresMMorrisTWSahmDFMonitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance studyAm J Ophthalmol2011152456757421652021
   PubMed Web of Science ®Google Scholar
• DrlicaKMalikMKernsRJZhaoXQuinolone-mediated bacterial deathAntimicrob Agents Chemother200852238539217724149
   PubMed Web of Science ®Google Scholar
• ShinabargerDLZurenkoGEHesjeCSanfilippoCMMorrisTWHaasWEvaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroquinolone besifloxacinJ Chemother201123808621571623
   PubMed Web of Science ®Google Scholar
• ComstockTLKarpeckiPMMorrisTWZhangJZBesifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitisClin Ophthalmol2010421522520463787
   PubMedGoogle Scholar
• BauernfeindAComparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacinJ Antimicrob Chemother19974056396519421311
   PubMed Web of Science ®Google Scholar
• DalhoffAComparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118Clin Infect Dis200132Suppl 1S16S2211249824
   PubMed Web of Science ®Google Scholar
• LuTZhaoXLiXEnhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureusAntimicrob Agents Chemother200145102703270911557458
   PubMed Web of Science ®Google Scholar
• HaasWPillarCPZurenkoGELeeJCBrunnerLSMorrisTWBesifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteriaAntimicrob Agents Chemother20095383552356019506065
   PubMed Web of Science ®Google Scholar
• SanfilippoCMHesjeCKHaasWMorrisTWTopoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacinChemotherapy201157536337121996946
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards InstitutePerformance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement M100-S212011Wayne, PAClinical and Laboratory Standards Institute2011
   Google Scholar
• Clinical and Laboratory Standards InstituteMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard, Eighth Edition. CLSI Document M7-A8Wayne, PAClinical and Laboratory Standards Institute2009
   Google Scholar
• Clinical and Laboratory Standards InstituteMethods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. CLSI Document M26-AWayne, PAClinical and Laboratory Standards Institute1999
   Google Scholar
• HaasWPillarCMHesjeCKSanfilippoCMMorrisTWBactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzaeJ Antimicrob Chemother20106571441144720435780
   PubMed Web of Science ®Google Scholar
• WiseRBrenwaldNPAndrewsJMBoswellFThe activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolonesJ Antimicrob Chemother19973944474529145816
   PubMed Web of Science ®Google Scholar
• HosakaMYasueTFukudaHTomizawaHAoyamaHHiraiKIn vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinoloneAntimicrob Agents Chemother19923610210821171332587
   PubMed Web of Science ®Google Scholar
• WakabayashiEMitsuhashiSIn vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinoloneAntimicrob Agents Chemother19943835946018203860
   PubMed Web of Science ®Google Scholar
• FassRJIn vitro activity of Bay y 3118, a new quinoloneAntimicrob Agents Chemother19933711234823578285618
   PubMed Web of Science ®Google Scholar
• MolinariGSchitoGCComparative in vitro activity of BAY Y 3118 with other fluoroquinolonesDrugs199549Suppl 22222258549310
   PubMedGoogle Scholar
• FukudaHHoriSHiramatsuKAntibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureusAntimicrob Agents Chemother1998428191719229687384
   PubMed Web of Science ®Google Scholar
• BaxBDChanPFEgglestonDSType IIA topoisomerase inhibition by a new class of antibacterial agentsNature2010466730993594020686482
   PubMed Web of Science ®Google Scholar
• PanXSFisherLMDNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniaeAntimicrob Agents Chemother19984211281028169797208
   PubMed Web of Science ®Google Scholar
• YoshidaHBogakiMNakamuraMYamanakaLMNakamuraSQuinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coliAntimicrob Agents Chemother1991358164716501656869
   PubMed Web of Science ®Google Scholar
• TakenouchiTTabataFIwataYHanzawaHSugawaraMOhyaSHydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureusAntimicrob Agents Chemother1996408183518428843290
   PubMed Web of Science ®Google Scholar
• SchmidtUSchlüterGStudies on the mechanism of phototoxicity of BAY y 3118 and other quinolonesAdv Exp Med Biol19963871171208794202
   PubMedGoogle Scholar
• BallPMandellLNikiYTillotsonGComparative tolerability of the newer fluoroquinolone antibacterialsDrug Saf199921540742110554054
   PubMed Web of Science ®Google Scholar
• SilverLHWoodsideAMMontgomeryDBClinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitisSurv Ophthalmol200550Suppl 1S55S6316257311
   PubMedGoogle Scholar
• McDonaldMBProtzkoEEBrunnerLSEfficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitisOphthalmology200911691615162319643483
   PubMed Web of Science ®Google Scholar
• ComstockTLPaternoMRUsnerDWPichicheroMEEfficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trialsPaediatr Drugs201012210511220218747
   PubMedGoogle Scholar
• ComstockTLPaternoMRDecoryHHUsnerDWSafety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studiesClin Drug Investig20103010675685
   Web of Science ®Google Scholar